Provectus Biopharmaceuticals filings document governance, capital-structure actions, and material-event disclosures for a clinical-stage biotechnology issuer focused on rose bengal sodium-based medicines. Proxy materials cover annual-meeting voting matters, board elections, stock ownership, director and officer interests, and related-party transaction disclosures.
Form 8-K reports record corporate events such as annual-meeting announcements and amendments to the certificates of designation for Series D and Series D-1 Convertible Preferred Stock. These filings also describe preferred-stock conversion terms, common-stock implications, exhibit filings, and the company’s use of press releases to furnish updates tied to public-company reporting.
Provectus Biopharmaceuticals, Inc. amended the terms of its Series D and Series D-1 Convertible Preferred Stock to push back when these preferred shares automatically convert into common stock. The automatic conversion date, previously set at June 20, 2026, is now December 31, 2028.
The amendments were approved by the board of directors and a special committee made up entirely of independent directors, and were filed with the Delaware Secretary of State. The changes affect only the timing of automatic conversion, not the existence of the preferred stock itself.
Provectus Biopharmaceuticals CEO Edward Pershing converted debt into equity-linked securities. On January 30, 2026, an 8% unsecured convertible promissory note called the 2025 Note converted into 37,744 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred stock will automatically convert into common stock on June 20, 2026 unless converted earlier under its terms. After this transaction, Pershing directly beneficially owned 2,578,867 shares of Series D-1 Convertible Preferred Stock.
Provectus Biopharmaceuticals CEO and director Edward Pershing reported acquiring an 8% unsecured convertible promissory note on January 28, 2026. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
The note’s outstanding principal and interest will automatically convert into Series D-1 Convertible Preferred Stock twelve months after its issue date, pursuant to the company’s 2025 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms.
Provectus Biopharmaceuticals CEO Edward Pershing reported a debt-for-equity conversion tied to prior financing. On January 16, 2026, an 8% unsecured convertible promissory note with $100,000 of outstanding principal and interest converted into 37,744 shares of Series D-1 Convertible Preferred Stock at $2.862 per share under the issuer's 2025 Financing. Each share of this preferred stock is convertible into 10 shares of common stock, and the Series D-1 Convertible Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier under its terms. Following this transaction, Pershing directly beneficially owned 2,541,123 derivative securities as reported in the Form 4.
Provectus Biopharmaceuticals, Inc. CEO and director Edward Pershing reported an insider transaction dated 12/11/2025 involving an 8% unsecured convertible promissory note. This note is treated as a derivative security linked to the company’s Series D-1 Convertible Preferred Stock.
Pershing may elect at any time to convert the note’s outstanding principal and interest into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share. If he does not act earlier, the note will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock and will automatically convert into common stock on June 26, 2026, unless converted sooner according to its terms.
Provectus Biopharmaceuticals, Inc. reported an insider financing transaction involving its CEO and director, Edward Pershing. On 12/05/2025, he acquired an 8% unsecured convertible promissory note with an amount of $ 75,000. The note can be converted at any time into shares of Series D-1 Convertible Preferred Stock at a price of $ 2.862 per share, and will automatically convert into that preferred stock twelve months after its issue date as part of the company’s 2025 Financing.
Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Provectus common stock. The Series D-1 preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under the terms of the Series D-1 Certificate of Designation. This transaction increases the CEO’s potential future equity exposure through layered conversions from debt to preferred stock and then to common shares.
Provectus Biopharmaceuticals, Inc. executive Dominic Rodrigues has filed a Schedule 13D reporting beneficial ownership of 25,220,549 shares of common stock, equal to 5.67% of the company’s outstanding common stock. This ownership includes shares held directly, through a retirement plan, jointly with his spouse, as custodian for children, and a large number of shares issuable from existing derivative securities.
The filing notes 13,378,760 shares of common stock are issuable upon conversion of 1,337,876 shares of Series D-1 Convertible Preferred Stock and 10,764,400 shares are issuable upon exercise of currently exercisable stock options. On December 2, 2025, 5,382,200 of his previously granted stock options vested. Rodrigues acquired these securities for investment purposes and, as Vice-Chairman and President, may influence the issuer’s corporate activities but states he has no specific current plans for major corporate transactions.
Provectus Biopharmaceuticals, Inc. and major holder Edward Pershing report updated ownership in an Amendment No. 2 to Schedule 13D. As of this amendment, Pershing beneficially owns 49,255,894 shares of common stock, representing 10.56% of Provectus’s outstanding common shares. This total includes common stock held directly and through retirement accounts, shares issuable from stock options exercisable within 60 days, and shares issuable upon conversion of Series D-1 Convertible Preferred Stock and secured convertible promissory notes. The filing also notes that from April 2018 to November 26, 2025, Provectus issued Pershing an aggregate principal amount of $7,117,500 in secured convertible promissory notes, and details multiple note purchases in late 2025 under the company’s 2025 Financing.
Provectus Biopharmaceuticals, Inc. reported a Form 4 transaction by its CEO and director, Edward Pershing, involving an 8% unsecured convertible promissory note tied to the company’s 2025 financing. On 11/26/2025, the reporting person acquired a note with principal of $70,000 that is convertible into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
The filing states that the note’s outstanding principal and interest may be converted into Series D-1 Preferred Stock at any time while it is outstanding, and will automatically convert at the same price per share twelve months after the note’s issue date. Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock, and the preferred shares will automatically convert into common stock on June 26, 2026, unless converted earlier under their terms.
Provectus Biopharmaceuticals, Inc. (PVCT) reported an insider financing transaction by CEO and director Edward Pershing. On 11/20/2025, Pershing acquired an 8% unsecured convertible promissory note with a principal amount of $30,000, convertible into Series D-1 Convertible Preferred Stock at $2.862 per share. This allows voluntary conversion of the note’s outstanding principal and interest into Series D-1 Preferred at that price while the note is outstanding, and it will automatically convert into preferred shares twelve months after the issue date.
Each share of Series D-1 Preferred is convertible into 10 shares of PVCT common stock. The Series D-1 Preferred will automatically convert into common stock on June 26, 2026, unless converted earlier under its terms. The transaction is part of the issuer’s 2025 financing.